Sarcoma

Evaluating the Activity of Trabectedin and Radiotherapy in Sarcoma

June 19, 2020

Alessandro Gronchi, MD, discusses a phase 2 trial of trabectedin and radiotherapy in patients with soft-tissue sarcoma.

Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS

June 02, 2020

Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Treatment Options Evolve for Patients With Desmoid Fibromatosis

May 18, 2020

Neeta Somaiah, MD, discusses the evolution of treatment options for patients with a unique sarcoma.

FDA Approves Pomalidomide for Treatment of Kaposi Sarcoma

May 15, 2020

Pomalidomide is now FDA approved for treatment of Kaposi sarcoma under multiple indications.

Patients With Pretreated Sarcoma May Derive Benefit From Various Immunotherapy Combinations

April 15, 2020

Combination therapy strategies involving immune checkpoint inhibitors and a secondary agent have shown promise across sarcoma subtypes, according to analysis of clinical trial data that were presented at the European Society for Medical Oncology Sarcoma & GIST Symposium 2020, held in Milan, Italy.

Cabozantinib May Be a New Therapeutic Option for Ewing Sarcoma and Osteosarcoma

April 03, 2020

Cabozantinib demonstrated antitumor activity as treatment of patients with advanced Ewing sarcoma and osteosarcoma, warranting further investigation for a potential new therapeutic option for this patient population, according to findings from phase II CABONE study.

Immunotherapy Induces Responses in Subtypes of Sarcomas

March 28, 2020

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Genetic Profiling Suggests Rationale for Limited Response to Immunotherapy in Osteosarcoma

February 22, 2020

Treatment with immune checkpoint inhibitors appears to elicit limited clinical activity in patients with osteosarcoma. In a study, investigators at MD Anderson Cancer Center found that certain factors like poor infiltration of the tumor by immune cells, low activity from available T cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways may interfere with response to immunotherapy in these patients, according to a press release from the organization.

A Look Back at FDA News from January 2020

February 08, 2020

In January 2020, the FDA approved new treatment options in gastrointestinal stromal tumors, bladder cancer, and epithelioid sarcoma. The FDA also granted several Priority Review Designations, orphan drug designations, and a Fast Track designation, as well as a Breakthrough Therapy designation.

Immunotherapy Combination Induces Promising ORR in Patients With Advanced Sarcoma

February 05, 2020

The combination of talimogene laherparepvec plus pembrolizumab led to a promising objective response rate in patients with advanced sarcoma who typically have limited treatment options, according to a phase II clinical trial published in JAMA Oncology.